24/7 Market News Snapshot 20 March, 2025 – MAIA Biotechnology, Inc. (NYSE:MAIA)

March 20, 2025

DENVER, Colo., 20 March, 2025 (247marketnews.com) – (NYSE:MAIA) are discussed in this article.
MAIA Biotechnology, Inc. has experienced a remarkable trading session with its shares opening at $1.88 and currently trading at $1.885, reflecting a noteworthy increase of 7.71% from the previous close of $1.750. This surge is accompanied by a substantial trading volume of 556.47K, underscoring strong investor interest and indicating a bullish momentum. The recent price movement suggests a potential reversal following a period of consolidation, and if MAIA maintains its position above the $1.88 level, it may attract further buyers, targeting resistance levels beyond $2. Key support has been established around $1.75, offering a safety net for investors.

In a significant development, MAIA has announced the publication of preclinical data in Naunyn-Schmiedeberg’s Archives of Pharmacology, showcasing the efficacy of its lead compound, THIO, particularly its novel dimerized form as a strong inhibitor of Glutathione S-transferase Pi (GSTP1). This enzyme is crucial in cancer progression and chemotherapeutic resistance. The study, titled “Investigation of the inhibitory effects of the telomere-targeted compounds on glutathione S-transferase P1,” illustrates that the dimerized version of THIO may enhance the effectiveness of existing chemotherapies by targeting GSTP1, thereby reducing resistance.

Dr. Vlad Vitoc, MAIA’s CEO, conveyed enthusiasm regarding the findings, emphasizing the compound’s favorable binding affinity and potency. The second-generation platform further aims to identify new telomere-targeting agents that exhibit increased specificity for cancer cells while sparing normal cells, with over 80 THIO-like candidates already developed. Dr. Sergei Gryaznov, Chief Scientific Officer, accentuated the transformative potential of the THIO dimer, which could significantly bolster current cancer treatment protocols. As MAIA continues to innovate, its dedication to improving patient outcomes in the fight against cancer remains resolute.

Related news for (MAIA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.